Royal Bank Of Canada restated their buy rating on shares of Imperva Inc (NYSE:IMPV) in a research report released on Wednesday, October 18th. The brokerage currently has a $49.00 target price on the software maker’s stock.
Other equities research analysts have also recently issued research reports about the stock. Monness Crespi & Hardt boosted their target price on shares of Imperva from $55.00 to $57.00 and gave the company a buy rating in a report on Friday, July 28th. Evercore ISI set a $56.00 target price on shares of Imperva and gave the company a buy rating in a report on Friday, July 28th. Piper Jaffray Companies set a $58.00 target price on shares of Imperva and gave the company a buy rating in a report on Monday, August 28th. BidaskClub lowered shares of Imperva from a strong-buy rating to a buy rating in a research report on Wednesday, July 5th. Finally, Stifel Nicolaus restated a hold rating and set a $47.00 price target on shares of Imperva in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $51.23.
Imperva (NYSE:IMPV) traded down 1.07% during midday trading on Wednesday, hitting $41.75. The stock had a trading volume of 410,521 shares. The stock has a 50-day moving average of $43.56 and a 200-day moving average of $45.92. Imperva has a 52 week low of $34.40 and a 52 week high of $52.40. The firm’s market cap is $1.41 billion.
Imperva (NYSE:IMPV) last issued its earnings results on Thursday, July 27th. The software maker reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.15). Imperva had a negative net margin of 4.69% and a negative return on equity of 5.00%. The business had revenue of $74.44 million for the quarter, compared to the consensus estimate of $74.30 million. During the same period in the previous year, the firm earned ($0.23) EPS. The company’s revenue was up 28.6% compared to the same quarter last year. Analysts forecast that Imperva will post $0.85 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Imperva’s (NYSE:IMPV) “Buy” Rating Reiterated at Royal Bank Of Canada” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/28/imperva-inc-impv-given-buy-rating-at-royal-bank-of-canada.html.
In other Imperva news, Director Anthony J. Bettencourt sold 99,598 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $43.59, for a total transaction of $4,341,476.82. Following the completion of the sale, the director now directly owns 99,598 shares in the company, valued at $4,341,476.82. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 2.20% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. bought a new position in shares of Imperva during the first quarter valued at about $102,000. First Quadrant L P CA bought a new position in shares of Imperva during the third quarter valued at about $136,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Imperva by 26.2% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock valued at $201,000 after acquiring an additional 866 shares during the last quarter. Amalgamated Bank bought a new position in shares of Imperva during the second quarter valued at about $206,000. Finally, Principal Financial Group Inc. bought a new position in shares of Imperva during the second quarter valued at about $223,000. Institutional investors and hedge funds own 92.72% of the company’s stock.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Imperva Inc and related companies with MarketBeat.com’s FREE daily email newsletter.